Skip to main content

XOMA Royalty Corp (XOMA.D)

No longer listed. Deregistered with the SEC on 2026-07-16; it traded as XOMA. Its history below is kept as recorded. All companies no longer listed
Sector
Healthcare
Industry
Biotechnology
Last price
$40.17
As of

Kresmion compiles this page from XOMA.D's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.

XOMA Royalty Corp (XOMA.D): 3 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-07-14.

As of . Source: SEC EDGAR filings for XOMA.D. Method and limitations.

COMPANY DOSSIER

See the full XOMA.D dossier

Price with insider and filing markers, who is positioning, fundamentals and peers for XOMA.D on one page. Preview it with sample data, then open it live with a free account.

Preview the XOMA.D dossier

Active signals for XOMA.D

No recent signals on XOMA.D in the last 180 days.

FREE, NO ACCOUNT

Every signal on XOMA.D, as it fires

New filings, 13F moves and cross asset signals on XOMA.D land in the record first.

Get it by email

No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.

Join on Telegram
Join on Telegram

One tap. Live alerts, no email needed.

Largest reported share positions in XOMA.D (2026Q2)

Manager / securityMarket value% portfolioQoQ
MILLENNIUM MANAGEMENT LLCCUSIP 98419J206 · 2026Q2$8.3M0.00%,
TWO SIGMA INVESTMENTS, LPCUSIP 98419J206 · 2026Q2$1.6M0.00%,
CITADEL ADVISORS LLCCUSIP 98419J206 · 2026Q2$1.2M0.00%,

Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.

Recent SEC filings, XOMA.D

XOMA.D against its peers

XOMA.D's operating margin of 110.0% ranks in the 96th percentile of 11 Biotechnology sub-industry peers, fiscal periods ending between 2025-03-31 and 2025-12-31.

MetricXOMA.DPeer medianPercentilen
Revenue FY10.3M USD46.3M USD2712
Operating margin110.0%-187.2%9611
Net margin306.4%-164.4%9611
Return on equity37.8%-45.3%9322

Peers (22): MDXG, CADL, FDMT, SLDB, VSTM, ACHV, GYRE, LXRX, ANNX, PHAR, SANA, ZVRA, HELP, IMMX, ABUS, AURA, DSGN, PRME, OLMA, WVE, AVTX, GERN. Left out: IVA (period gap), ANL (period gap), OBX (no annual filing). Fiscal periods ending between 2025-03-31 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (XOMA.D: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.

Related tickers

Follow XOMA.D on a live board

Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to XOMA.D for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.

Preview the XOMA.D dossier
Share

The XOMA.D intelligence card: the smart money composite, cross family confluence and the top current signal, with a link back to this page.